Juvena Therapeutics
PrivateLast Round
Series B
Jan 12, 2026
Est. Valuation
$111M
Total Funding Raised
$143.66M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Juvena Therapeutics is a biotechnology company that develops AI-enabled regenerative biologics to restore tissue function and treat chronic and age-related diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Juvena Therapeutics Comparables
Compare Juvena Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Entrada Therapeutics | 78% | |
| Avidity Biosciences | 77% | |
| PepGen | 76% |
Juvena Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 12, 2026 | ||||
| Series B | Jul 24, 2025 | ||||
| Series A | Nov 8, 2022 | ||||
| Grant | Feb 2, 2022 | ||||
| Grant | Aug 1, 2021 | ||||
Seed | Feb 26, 2018 |
Juvena Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Horizons Ventures | Series B, Series A |
| NIH RADx | Grant |
| Plum Alley Investments | Series A |
| Intersect VC | Series A |
| Intersect Capital | Series A |
| Jefferson Life Sciences | Series B |
| California Institute for Regenerative Medicine | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 44% MoM.
- Jan 12, 2026
$34M round completed.
Recent news
Latest coverage and updates
- hiresAug 17, 2026
Juvena Therapeutics, Inc. hired Smith as Chief Executive Officer on Aug 17th '26.
- hiresAug 17, 2026
Juvena Therapeutics, Inc. hired Julie Anne Smith as Chief Executive Officer on Aug 17th '26.
Juvena Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Juvena Therapeutics's valuation, stock price, and market status.
Is Juvena Therapeutics a public or private company?
Juvena Therapeutics is a private company.
What is the current stock price of Juvena Therapeutics?
Juvena Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Juvena Therapeutics worth (valuation)?
Juvena Therapeutics's valuation is estimated at $111.0M based on funding round data.
Can I buy Juvena Therapeutics stock?
Juvena Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Juvena Therapeutics's last funding round?
Juvena Therapeutics's most recent funding round was Series B on July 24, 2025.
Who are the main investors in Juvena Therapeutics?
Key investors in Juvena Therapeutics include Horizons Ventures, Jefferson Life Sciences, Mubadala Capital, Bison Ventures.
Will Juvena Therapeutics IPO soon?
No public IPO plans have been announced for Juvena Therapeutics.
How can I track Juvena Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Juvena Therapeutics's secondary market activity and sign up for updates.